Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab ; volume:25 ; number:1 ; day:27 ; month:4 ; year:2023 ; pages:1-11 ; date:12.2023
Arthritis Research & Therapy ; 25, Heft 1 (27.4.2023), 1-11, 12.2023
- Urheber
-
Kim, Seong-Kyu
Lee, Sang-Heon
Sun, Jiyu
Lee, Soo Hyun
Jeon, Ja-Young
Yoo, Hyun-Jeong
Choe, Jung-Yoon
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-023-03047-1
- URN
-
urn:nbn:de:101:1-2023090321105305746818
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Seong-Kyu
- Lee, Sang-Heon
- Sun, Jiyu
- Lee, Soo Hyun
- Jeon, Ja-Young
- Yoo, Hyun-Jeong
- Choe, Jung-Yoon
- SpringerLink (Online service)
Ähnliche Objekte (12)
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Refractory necrotizing scleritis successfully treated with adalimumab
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Inequality Comparisons with Ordinal Data
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Refractory necrotizing scleritis successfully treated with adalimumab
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Inequality Comparisons with Ordinal Data
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Refractory necrotizing scleritis successfully treated with adalimumab
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Inequality Comparisons with Ordinal Data
High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib